INT34596

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.36
First Reported 1983
Last Reported 2004
Negated 1
Speculated 1
Reported most in Abstract
Documents 5
Total Number 7
Disease Relevance 3.26
Pain Relevance 2.27

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

structural molecule activity (Des) cytoskeleton (Des) intracellular (Des)
cytoplasm (Des)
Anatomy Link Frequency
paw 2
uterine 1
myotubes 1
Des (Mus musculus)
Pain Link Frequency Relevance Heat
bradykinin 16 99.96 Very High Very High Very High
Pain 10 99.04 Very High Very High Very High
antagonist 4 94.76 High High
agonist 12 91.28 High High
Potency 27 90.08 High High
Dismenorea 1 82.52 Quite High
tetrodotoxin 5 76.16 Quite High
B1 receptor 6 75.00 Quite High
Spinal cord 1 70.40 Quite High
Bioavailability 3 52.96 Quite High
Disease Link Frequency Relevance Heat
Pressure And Volume Under Development 14 99.44 Very High Very High Very High
Aging 1 99.16 Very High Very High Very High
Pain 6 99.04 Very High Very High Very High
Adenocarcinoma 4 96.92 Very High Very High Very High
Uterine Fibroids 1 91.40 High High
Cancer 7 86.48 High High
Dysmenorrhea 1 82.52 Quite High
Metaplasia 1 81.88 Quite High
Congenital Anomalies 13 80.60 Quite High
Targeted Disruption 60 78.56 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In mutant myotubes the desmin network remains in a diffuse position and does not reorganize itself transversely, as it does during normal myogenesis.
desmin Neg (not) Binding (reorganize) of in myotubes
1) Confidence 0.36 Published 1988 Journal Dev. Biol. Section Abstract Doc Link 3044880 Disease Relevance 0.30 Pain Relevance 0.37
Thus the effects of prenatal exposure to DES interacted with the effects of aging to produce a relatively high frequency of uterine adenocarcinoma.
DES Binding (interacted) of in uterine associated with adenocarcinoma and aging
2) Confidence 0.31 Published 1983 Journal J. Natl. Cancer Inst. Section Abstract Doc Link 6572737 Disease Relevance 0.97 Pain Relevance 0.08
have the same affinity for DES and BPA (Matthews et al. 2000), and this is likely to be the case for ER-?
DES Binding (affinity) of
3) Confidence 0.11 Published 2004 Journal Environ Health Perspect Section Body Doc Link PMC1247619 Disease Relevance 0.05 Pain Relevance 0.15
With the IVIS measurements, we observed a difference between DES and EP in the kinetics of inducing luciferase activity (Figure 3).
DES Binding (difference) of
4) Confidence 0.09 Published 2004 Journal Environ Health Perspect Section Body Doc Link PMC1247619 Disease Relevance 0 Pain Relevance 0
In the present study, we used this model to examine the ability of BPA—in comparison with known strong estrogens DES and 17?
DES Spec (examine) Binding (comparison) of
5) Confidence 0.09 Published 2004 Journal Environ Health Perspect Section Body Doc Link PMC1247619 Disease Relevance 0.32 Pain Relevance 0
The pain response and oedema formation caused by i.p.l. co-injection of des-Arg9-bradykinin, together with formalin in BCG-pre-treated animals, were dose-dependently antagonised by i.p.l. co-injection of the B1 antagonist des-Arg9[Leu8]bradykinin (1-15 nmol/paw), but were not affected by the B2 antagonist Hoe 140 (10 nmol/paw).
des-Arg9 Binding (co-injection) of in paw associated with pain, pressure and volume under development, antagonist and bradykinin
6) Confidence 0.02 Published 1998 Journal Neuropeptides Section Abstract Doc Link 9844998 Disease Relevance 0.80 Pain Relevance 0.84
The pain response and oedema formation caused by i.p.l. co-injection of des-Arg9-bradykinin, together with formalin in BCG-pre-treated animals, were dose-dependently antagonised by i.p.l. co-injection of the B1 antagonist des-Arg9[Leu8]bradykinin (1-15 nmol/paw), but were not affected by the B2 antagonist Hoe 140 (10 nmol/paw).
des-Arg9 Binding (co-injection) of in paw associated with pain, pressure and volume under development, antagonist and bradykinin
7) Confidence 0.02 Published 1998 Journal Neuropeptides Section Abstract Doc Link 9844998 Disease Relevance 0.80 Pain Relevance 0.84

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox